Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rockwell Medical, MEDNAX, and Pinduoduo, and Encourages Investors to Contact the Firm
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Rockwell Medical, Inc., MEDNAX, Inc., and Pinduoduo Inc. Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Rockwell Medical, Inc. (RMTI)
Class Period: September 9, 2015 - February 29, 2016
Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that throughout the Class Period, Defendants issued false and misleading statements to investors and failed to disclose that: (1) the primary product offering for Triferic will be in a powder packet packaging that the FDA has not yet approved; (2) Rockwell is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement; and (3) as a result, Defendants’ statements about Rockwell’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Rockwell class action go to: http://bespc.com/rmti/.
MEDNAX, Inc. (MD)
Class Period: February 2, 2016 - July 27, 2017
Lead Plaintiff Deadline: September 10, 2018
The complaint alleges that on July 28, 2017, Mednax announced, during its second quarter earnings call with investors and analysts, that the company had failed to complete any acquisitions of anesthesiologist practices during the quarter. Significantly, the company also disclosed that any future anesthesiologist acquisitions were unlikely, which Mednax attributed to the “challenging” payor mix combined with “continued . . . growth in compensation expense for nurse anesthetists.”
To learn more about the MEDNAX class action go to: https://bespc.com/mednax/.
Pinduoduo Inc. (PDD)
Class Period: July 23, 2018 - August 21, 2018
Lead Plaintiff Deadline: October 22, 2018
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. In the Registration Statement and Prospectus issued in connection with Pinduoduo’s IPO, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Pinduoduo’s controls were ineffective to prevent third-party vendors from selling counterfeit goods on the Company’s online platform; (2) consequently, Pinduoduo’s revenues and the number of active merchants using its platform were traceable in part to unlawful conduct and thus unsustainable; and (3) as a result, Pinduoduo’s public statements were materially false and misleading at all relevant times.
To learn more about the Pinduoduo class action go to: http://bespc.com/pdd/.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.